<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03379792</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 1144866</org_study_id>
    <nct_id>NCT03379792</nct_id>
  </id_info>
  <brief_title>The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes</brief_title>
  <acronym>ACME</acronym>
  <official_title>The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the metabolic phenotype of a range of body weights in
      individuals with and without Type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidation of energy expenditure</measure>
    <time_frame>24 hours</time_frame>
    <description>The values acquired from the metabolic chamber will be measured using a computer system (PiLR™) that stores the data. This computer system will then calculate the VO2 and convert it into EE (kcal/minute).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Lean T1D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese T1D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DEXA</intervention_name>
    <description>Measurement of body composition by Dual Energy X-ray Absorptiometry (DEXA)</description>
    <arm_group_label>Lean T1D</arm_group_label>
    <arm_group_label>Non-diabetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Whole body magnetic resonance imaging (MRI)</description>
    <arm_group_label>Lean T1D</arm_group_label>
    <arm_group_label>Non-diabetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CGM</intervention_name>
    <description>A continuous glucose monitor (CGM) will be placed on the participant and will be used as a safety measure to monitor glucose levels.</description>
    <arm_group_label>Lean T1D</arm_group_label>
    <arm_group_label>Non-diabetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole room calorimeters</intervention_name>
    <description>Whole room indirect calorimetry allows for the simultaneous measure of total energy expenditure and substrate oxidation in a free living environment with multiple activities.</description>
    <arm_group_label>Lean T1D</arm_group_label>
    <arm_group_label>Obese T1D</arm_group_label>
    <arm_group_label>Non-diabetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary counseling</intervention_name>
    <description>The low carbohydrate diet counseling will be to assist young adult, overweight study participants with Type 1 diabetes in adhering to a lower calorie diet (500 calorie deficit)</description>
    <arm_group_label>Obese T1D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, 19 to 30 years of age, inclusive.

          2. Type 1 Diabetes Cohort:

               -  Diagnosis of type 1 diabetes for greater than 1 year at screening.

               -  Hemoglobin A1c 6.5-13% or

          3. Non-Diabetic Control Cohort:

               -  Healthy individuals (non-diabetic) matched to T1D cohort by BMI, and gender

        3. Able to provide informed consent. 4. BMI 18-39

        Exclusion Criteria:

          1. Type 2 diabetes

          2. History or presence of cardiovascular disease (unstable angina, myocardial infarction
             or coronary revascularization within 6 months, clinically significant abnormalities on
             EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)

          3. Liver disease (AST or ALT &gt;2.5 times the upper limit of normal), history of hepatitis

          4. Kidney disease (creatinine &gt;1.6 mg/dl or estimated glomerular filtration rate (GFR)&lt;60
             ml/min)

          5. Dyslipidemia, including triglycerides &gt;800 mg/dl, LDL &gt;200 mg/dl

          6. Anemia (hemoglobin &lt;12 g/dl in men, &lt;11 g/dl in women)

          7. Thyroid dysfunction (suppressed thyroid-stimulating hormone (TSH), elevated TSH &lt;10
             µIU/ml if symptomatic or elevated TSH &gt;10 µIU/ml if asymptomatic)

          8. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt; 100mmHg diastolic)

          9. History of cancer within the last 5 years (skin cancers, with the exception of
             melanoma, may be acceptable).

         10. Initiation or change in hormone replacement therapy within the past 3 months
             (including, but not limited to thyroid hormone, birth control or estrogen replacement
             therapy)

         11. History of organ transplant

         12. History of HIV, active Hepatitis B or C, or Tuberculosis

         13. Pregnancy, lactation or 6 months postpartum from screening visit

         14. History of major depression

         15. Psychiatric disease prohibiting adherence to study protocol

         16. History of eating disorders

         17. Cushing's disease or syndrome

         18. History of bariatric surgery

         19. Tobacco use within the past 3 months

         20. History of drug or alcohol abuse (≥3 drinks per day) within the last 5 years

         21. Use of oral or injectable anti-hyperglycemic agents (except insulin)

         22. Current use of beta-adrenergic blocking agents

         23. Use of antibiotics within the past 3 months

         24. Weight &gt;450 lbs (This is DEXA table weight limit)

         25. Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at
             screening

         26. Unable to participate in MRI or magnetic resonance spectroscopy (MRS) assessment based
             on Investigator's judgment at screening

         27. Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple
             food allergies, or allergies to food we will provide them during the study)

         28. Gastrointestinal disorders including: inflammatory bowel disease or malabsorption,
             swallowing disorders, suspected or known strictures, fistulas or
             physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's
             disease or diverticulitis.

         29. Presence of any condition that, in the opinion of the investigator, compromises
             participant safety or data integrity or the participant's ability to complete study
             visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Pratley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study principal investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quianna Stokes- Washington</last_name>
    <phone>407-303-3688</phone>
    <email>tri@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quianna Stokes- Washington</last_name>
      <phone>407-303-3688</phone>
      <email>tri@flhosp.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078.</citation>
    <PMID>25998289</PMID>
  </reference>
  <reference>
    <citation>Chillarón JJ, Benaiges D, Mañé L, Pedro-Botet J, Flores Le-Roux JA. Obesity and type 1 diabetes mellitus management. Minerva Endocrinol. 2015 Mar;40(1):53-60. Epub 2014 Nov 21. Review.</citation>
    <PMID>25413942</PMID>
  </reference>
  <reference>
    <citation>Maahs DM, Ogden LG, Dabelea D, Snell-Bergeon JK, Daniels SR, Hamman RF, Rewers M. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia. 2010 Dec;53(12):2518-25. doi: 10.1007/s00125-010-1886-6. Epub 2010 Sep 4.</citation>
    <PMID>20820753</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.</citation>
    <PMID>19636033</PMID>
  </reference>
  <reference>
    <citation>Jacob AN, Salinas K, Adams-Huet B, Raskin P. Potential causes of weight gain in type 1 diabetes mellitus. Diabetes Obes Metab. 2006 Jul;8(4):404-11. Erratum in: Diabetes Obes Metab. 2006 Jul;8(4):472.</citation>
    <PMID>16776747</PMID>
  </reference>
  <reference>
    <citation>Rigalleau V, Lasseur C, Pécheur S, Chauveau P, Combe C, Perlemoine C, Baillet L, Gin H. Resting energy expenditure in uremic, diabetic, and uremic diabetic subjects. J Diabetes Complications. 2004 Jul-Aug;18(4):237-41.</citation>
    <PMID>15207844</PMID>
  </reference>
  <reference>
    <citation>Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes. 1993 Dec;42(12):1700-7.</citation>
    <PMID>8243815</PMID>
  </reference>
  <reference>
    <citation>Greco AV, Tataranni PA, Mingrone G, De Gaetano A, Manto A, Cotroneo P, Ghirlanda G. Daily energy metabolism in patients with type 1 diabetes mellitus. J Am Coll Nutr. 1995 Jun;14(3):286-91.</citation>
    <PMID>8586779</PMID>
  </reference>
  <reference>
    <citation>Nair KS, Halliday D, Garrow JS. Increased energy expenditure in poorly controlled Type 1 (insulin-dependent) diabetic patients. Diabetologia. 1984 Jul;27(1):13-6.</citation>
    <PMID>6147290</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

